From: Childhood Hodgkin Lymphoma Treatment (PDQ®)
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Table 6. Treatment Approaches for Patients With Low-Risk Hodgkin Lymphoma
| Chemotherapy (No. of Cycles)a | Radiation (Gy) | Stage | No. of Patients | Event-Free Survival (No. of Years of Follow-up) | Survival (No. of Years of Follow-up) |
|---|---|---|---|---|---|
| VAMP (4)b [46] | IFRT (15–25.5) | CS I/IIc | 110 | 89% (10) | 96% (10) |
| VAMP (4)b [54] | IFRT (25.5) | CS I/IIc | 41 | 88% (5) | 100% (5) |
| None | 47 | 89% (5) | |||
| COPP/ABV (4) [14,20] | IFRT (21) | CS IA/B, IIAd | 94 | 100% (10)e | 97% (10)e |
| None | 113 | 89% (10)e | 96% (10)e | ||
| OEPA/OPPA (2) [21] | IFRT (20–35) | I, IIA | 281 | 94% (5) | N/A |
| None | 113 | 97% (5) | |||
| ABVD [58] | IFRT (21–35) | I–IV | 209 | 85% (5) | 97% (5) |
| ABVE (2-4)b [48] | IFRT (25.5) | IA, IIA, IIIA1, without bulky disease | 51 | 91% (6) | 98% (6) |
| AV-PC [34] | None | IA, IIA, without bulky disease | 278 | 79.9% (4) | 99.6% (4) |
| Response-based IFRT (21) |
CS = clinical stage; IFRT = involved-field radiation therapy; N/A = not applicable; No. = number.
aRefer to Table 5 for more information about the chemotherapy regimens.
bIncluded patients with nodular lymphocyte-predominant Hodgkin lymphoma.
cWithout bulky mediastinal (defined as one-third or more of intrathoracic ratio measured on an upright posteroanterior chest radiograph) or peripheral lymphadenopathy (defined as 6 cm or more) or B symptoms.
dWithout adverse features, defined as one or more of the following: hilar adenopathy, involvement of more than four nodal regions; mediastinal tumor with diameter equal to or larger than one-third of the chest diameter, and node or nodal aggregate with a diameter larger than 10 cm.
eResults from as-treated analysis.